AYTU - Aytu BioScience Inc Stock Price, Fair Value and News

$2.10+0.05 (+2.44%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

AYTU Price Action

Last 30 days

-5.0%

Last 90 days

-7.1%

Trailing 12 Months

32.1%

AYTU RSI Chart

AYTU Valuation

Market Cap

21.4M

Price/Earnings (Trailing)

-1.64

Price/Sales (Trailing)

0.34

EV/EBITDA

0.14

Price/Free Cashflow

-13.43

AYTU Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AYTU Fundamentals

AYTU Revenue

Revenue (TTM)

63.7M

Rev. Growth (Yr)

-16.21%

Rev. Growth (Qtr)

-8.24%

AYTU Earnings

Earnings (TTM)

-13.1M

Earnings Growth (Yr)

33.31%

Earnings Growth (Qtr)

109.92%

AYTU Profitability

Operating Margin

35.31%

EBT Margin

-20.85%

Return on Equity

-56.41%

Return on Assets

-10.46%

Free Cashflow Yield

-7.45%

AYTU Investor Care

Shares Dilution (1Y)

65.68%

Diluted EPS (TTM)

-0.28

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	65.8M	66.4M	63.7M	0
2024	67.3M	65.2M	63.9M	61.4M
2023	104.1M	73.8M	71.6M	69.5M
2022	92.7M	96.7M	102.4M	105.6M
2021	57.0M	65.6M	74.0M	82.0M
2020	14.5M	27.6M	39.7M	51.7M
2019	6.5M	7.3M	7.3M	8.7M
2018	3.6M	3.7M	4.0M	4.8M
2017	3.3M	3.2M	3.6M	3.9M
2016	1.8M	2.6M	2.8M	3.1M
2015	110.2K	261.8K	721.6K	1.2M
2014	31.7K	45.3K	76.7K	92.5K
2013	33.6K	41.8K	18.1K	0
2012	0	0	17.2K	25.4K
2011	0	0	0	0
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Aytu BioScience Inc

Aytu Biopharma, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates into two segments Rx segment and Consumer Health segment. The Rx segment consisting of prescription pharmaceutical products sold through third party wholesalers. The Consumer Health segment, which consists of various consumer health products sell directly to consumers. It also offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. In addition, the company provides Karbinal ER, for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

CEO	Mr. Joshua R. Disbrow
WEBSITE	https://aytubio.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers Specialty & Generic
EMPLOYEES	164

Aytu BioScience Inc Frequently Asked Questions

What is the ticker symbol for Aytu BioScience Inc? What does AYTU stand for in stocks?

AYTU is the stock ticker symbol of Aytu BioScience Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aytu BioScience Inc (AYTU)?

As of Wed Dec 03 2025, market cap of Aytu BioScience Inc is 21.4 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AYTU stock?

You can check AYTU's fair value in chart for subscribers.

Is Aytu BioScience Inc a good stock to buy?

The fair value guage provides a quick view whether AYTU is over valued or under valued. Whether Aytu BioScience Inc is cheap or expensive depends on the assumptions which impact Aytu BioScience Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AYTU.

What is Aytu BioScience Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, AYTU's PE ratio (Price to Earnings) is -1.64 and Price to Sales (PS) ratio is 0.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AYTU PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Aytu BioScience Inc's stock?

In the past 10 years, Aytu BioScience Inc has provided -0.758 (multiply by 100 for percentage) rate of return.